Stop the Shortages

Phlow Recognizes National Essential Medicine Shortage Awareness Day

Sep 8, 2022 | Corporate Statements

Solving America’s drug shortage crisis continues to be a complex challenge that will take the effort, collaboration, and innovation of many to solve

Richmond, Virginia, September 8, 2022 – Phlow announced today that it will be observing National Essential Medicine Shortage Awareness Day (NEMSAD), a national observance day occurring each year on September 8, to bring awareness to the ongoing essential medicine shortage crisis in the United States and to create solutions that result in a reliable supply of high-quality medicines for all Americans. While medicine shortages have been a persistent challenge for the U.S. healthcare system for more than a decade, the COVID-19 pandemic has amplified vulnerabilities in the overall supply chain.

“Americans should not have to worry about the availability of essential medicines necessary to sustain life and conquer disease, but this is a reality faced by many patients today,” said Eric Edwards, President, and CEO of Phlow. “That’s why we stand strong in our support of NEMSAD and are proud to join its call to action to create domestic supply chain resiliency and reliability for our country’s most vital medicines. For us, NEMSAD is every day, and we are fortunate and honored to work with like-minded organizations who are focused and passionate about solving this issue.”

It is critical to national public health security that public-private partnerships are established to accelerate efforts to domestically manufacture essential medicines. The broken supply chain is a complex problem that no one approach can fix. By working together collaboratively, private companies, government stakeholders and the public, can forge a new path that will reduce our reliance on imported medicines and create a robust, secure supply chain for future generations.

Phlow is dedicated to ensuring that the care of America’s children, one of our most vulnerable patient populations, is not impacted by drug shortages. Phlow, along with over 20 of the nation’s leading children’s hospitals, is part of a one-of-a-kind collaboration called the Children’s Hospital Coalition (CHC). This first-in-kind coalition brings together some of the top children’s hospitals in the nation to raise awareness about the broken essential medicines supply chain for pediatric patients and to help provide a solution.

Together, Coalition members seek to solve the persistent problem of shortages of essential medicines plaguing children’s hospitals across the U.S. by identifying drugs in shortage and accumulating the common need volume to create a sustainable supply. As a result, the CHC provides certainty in availability, quality, access, and affordability for key medicines. It is this kind of collective action that represents the spirit of NEMSAD and serves as an example of what is possible when we work together to fix the nation’s broken essential medicines supply chain.

Solving for America’s drug shortages continues to be a complex challenge, one that Phlow is prepared to answer as evidenced by its key role in protecting America’s medicine cabinet to date and for generations to come. Every one of us can play an essential role in protecting American families—and our country—from current and future public health emergencies by working together to #stoptheshortages.

###

About Phlow

Phlow Corp. is a trailblazing, essential medicines impact company that is reimagining essential medicines from start to finish using flow chemistry and other advanced development and manufacturing processes. Everything Phlow does is designed to promote access to affordable, high-quality essential medicines for all Americans. Phlow provides a solution to the broken essential medicines supply chain by offering a resilient end-to-end solution that is U.S.-based, comprehensive, and fully integrated. With the support of an industry leading team, experienced strategic partners, and established relationships at the policy, regulatory, and federal levels, Phlow will develop and manufacture active pharmaceutical ingredients (APIs) and finished pharmaceutical products domestically for essential medicines critical to the nation’s healthcare. Using continuous-flow processes and other green chemistry approaches, Phlow is able to reduce costs and waste, improve quality and yield, and offer a more environmentally friendly alternative to batch manufacturing.